688 related articles for article (PubMed ID: 2472873)
21. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells.
Yoshida M; Matsui Y; Ikarashi Y; Usui T; Osada H; Wakasugi H
Anticancer Res; 2007; 27(2):729-36. PubMed ID: 17465195
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
[TBL] [Abstract][Full Text] [Related]
23. [Chemosensitivity of adriamycin, mitomycin C, and bleomycin with in vitro colony assay].
Miyamoto H; Inoue K; Arakawa M; Ogawa M
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1921-7. PubMed ID: 6191690
[TBL] [Abstract][Full Text] [Related]
24. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs.
Watanabe N; Niitsu Y; Yamauchi N; Ohtsuka Y; Sone H; Neda H; Maeda M; Urushizaki I
Immunopharmacol Immunotoxicol; 1988; 10(1):117-27. PubMed ID: 2452179
[TBL] [Abstract][Full Text] [Related]
25. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
26. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
[TBL] [Abstract][Full Text] [Related]
29. Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor.
Nakagawa M; Yamaguchi T; Fukawa H; Ogata J; Komiyama S; Akiyama S; Kuwano M
Jpn J Cancer Res; 1985 Apr; 76(4):315-20. PubMed ID: 2408954
[TBL] [Abstract][Full Text] [Related]
30. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
32. [Mechanism of action and resistance of antineoplastic agents].
Tanaka N
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2245-51. PubMed ID: 6195971
[TBL] [Abstract][Full Text] [Related]
33. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
34. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
Tsuruo T
Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
36. Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells.
Hamada H; Okochi E; Watanabe M; Oh-hara T; Sugimoto Y; Kawabata H; Tsuruo T
Cancer Res; 1988 Dec; 48(24 Pt 1):7082-7. PubMed ID: 2903793
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
38. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
Nishio K; Sugimoto Y; Nakagawa K; Niimi S; Fujiwara Y; Bungo M; Kasahara K; Fujiki H; Saijo N
Br J Cancer; 1990 Sep; 62(3):415-9. PubMed ID: 2206949
[TBL] [Abstract][Full Text] [Related]
39. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
[TBL] [Abstract][Full Text] [Related]
40. FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line.
Natazuka T
Kobe J Med Sci; 1992 Dec; 38(6):347-63. PubMed ID: 1284834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
